SUNNYVALE, California,
August 9, 2016 /PRNewswire/ --
Next Generation Image-Guided
Radiation Therapy Platform and Integrated Software Solutions are
Now Available for Use by Clinicians in the European
Union
Accuray Incorporated (NASDAQ: ARAY) announced today that it has
CE marked its Radixact™ Treatment Delivery System, Accuray
Precision™ Treatment Planning System and iDMS™ Data Management
System. The next generation hardware and software solutions,
together, make up the new Radixact platform, which represents a
major step forward in the evolution of Accuray's existing
TomoTherapy® System in treatment speed and ease of use.
The platform will now be available in certain markets in the
European Union (EU), in addition to the U.S. market where it
received FDA 510(k) clearance in June
2016.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://photos.prnewswire.com/prnh/20160809/396644 )
The Radixact System is a "smart" system that will enable faster,
more efficient delivery of extremely precise treatment to a wider
range of cancer patients across the European market. It features a
more powerful linear accelerator, MVCT imaging and helical
treatment delivery, so clinicians can apply highly conformal and
homogeneous dose distributions to any target volume, while
precisely sparing normal healthy tissue during each treatment
fraction.
"Radixact System availability in the EU is a critical component
of our commercial launch strategy for this innovative platform,"
said Joshua H. Levine, president and
chief executive officer of Accuray. "We have shipped the first
commercially released Radixact System to a site in the U.S. and
expect our first EU shipment during our Fiscal Q1 2017. The system
is a key driver of our short- and long-term growth outlook, as well
as our ability to achieve sustainable profitability, and we are
excited about the reception the system is receiving in the
marketplace."
The Radixact platform is comprised of three entirely new,
transformative technologies:
- Radixact Treatment Delivery System: Taking the
industry-leading capabilities of the TomoTherapy Systems to a new
level.
- Accuray Precision Treatment Planning System: Smart,
automated workflows and mid-course decision-making tools that
enable clinicians to adapt delivery according to changes in tumor
size, shape and location.
- iDMS Data Management System: Seamless management of
patient data across multiple Radixact Systems and clinics, from a
single point of control.
For Important Safety information about radiotherapy please refer
to:
http://www.accuray.com/safety-statement-radiation-treatment.
For more information about the Radixact platform, visit:
http://www.accuray.com/radixact.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
regulatory approvals and launches of new products, market uptake of
recently launched products, and Accuray's leadership position in
radiation oncology innovation and technologies. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from expectations, including
but not limited to the risks detailed from time to time under the
heading "Risk Factors" in the company's report on Form 10-K, filed
on August 28, 2015, the company's
reports on Form 10-Q, filed on November 5,
2015, February 1, 2016 and
April 29, 2016, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.